Risk-Benefit Analysis in a Multiobjective Framework

1981 ◽  
pp. 89-122 ◽  
Author(s):  
Yacov Y. Haimes
Keyword(s):  
Benefit Analysis ◽  
Risk Benefit Analysis

scholarly journals Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries

2011 ◽  
Vol 10 (1) ◽  
Author(s):  
Eduardo Massad ◽  
Ben C Behrens ◽  
Francisco AB Coutinho ◽  
Ronald H Behrens
Keyword(s):  
Benefit Analysis ◽  
Risk Benefit Analysis ◽  
Cost Risk

scholarly journals A risk–benefit analysis approach to seafood intake to determine optimal consumption

2011 ◽  
Vol 107 (12) ◽  
pp. 1812-1822 ◽  
Author(s):  
Véronique Sirot ◽  
Jean-Charles Leblanc ◽  
Irène Margaritis
Keyword(s):  
Arsenic Exposure ◽  
Inorganic Arsenic ◽  
Hierarchical Cluster ◽  
Good Health ◽  
Benefit Analysis ◽  
Food Contaminants ◽  
Public Health Perspective ◽  
Contaminant Exposure ◽  
Consumption Level ◽  
Risk Benefit Analysis

Seafood provides n-3 long-chain PUFA (n-3 LC-PUFA), vitamins and minerals, which are essential to maintain good health. Moreover, seafood is a source of contaminants such as methylmercury, arsenic and persistent organic pollutants that may affect health. The aim of the present study was to determine in what quantities seafood consumption would provide nutritional benefits, while minimising the risks linked to food contaminants. Seafood was grouped into clusters using a hierarchical cluster analysis. Those nutrients and contaminants were selected for which it is known that seafood is a major source. The risk–benefit analysis consisted in using an optimisation model with constraints to calculate optimum seafood cluster consumption levels. The goal was to optimise nutrient intakes as well as to limit contaminant exposure with the condition being to attain recommended nutritional intakes without exceeding tolerable upper intakes for contaminants and nutrients, while taking into account background intakes. An optimum consumption level was calculated for adults that minimises inorganic arsenic exposure and increases vitamin D intake in the general population. This consumption level guarantees that the consumer reaches the recommended intake for n-3 LC-PUFA, Se and I, while remaining below the tolerable upper intakes for methylmercury, Cd, dioxins, polychlorobiphenyls, Zn, Ca and Cu. This consumption level, which is approximately 200 g/week of certain fatty fish species and approximately 50 g/week of lean fish, molluscs and crustaceans, has to be considered in order to determine food consumption recommendations in a public health perspective.

Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohnʼs disease

2011 ◽  
Vol 17 (1) ◽  
pp. 127-140 ◽  
Author(s):  
Edward V. Loftus ◽  
Scott J. Johnson ◽  
Si-Tien Wang ◽  
Eric Wu ◽  
Parvez M. Mulani ◽  
...  
Keyword(s):  
Benefit Analysis ◽  
Biologic Therapies ◽  
Risk Benefit Analysis

Intravenous lidocaine: it's all about a risk‐benefit analysis

Anaesthesia ◽  
2021 ◽  
Author(s):  
M. W. Hollmann ◽  
H. Hermanns ◽  
P. Kranke ◽  
M. E. Durieux
Keyword(s):  
Benefit Analysis ◽  
Intravenous Lidocaine ◽  
Risk Benefit Analysis

scholarly journals Risk-benefit analysis in food safety and nutrition

2020 ◽  
Author(s):  
Jeanne Marie Membré ◽  
Sofia Santillana Farakos ◽  
Maarten Nauta
Keyword(s):  
Food Safety ◽  
Benefit Analysis ◽  
Risk Benefit Analysis

scholarly journals SSRI use in pregnancy: Evaluating the risks and benefits

2015 ◽  
Vol 21 (2) ◽  
pp. 6
Author(s):  
Elsa Du Toit ◽  
Eileen Thomas ◽  
Liezl Koen ◽  
Bavi Vythilingum ◽  
Stoffel Grobler ◽  
...  
Keyword(s):  
Antidepressant Treatment ◽  
Severe Depression ◽  
Evidence Base ◽  
Current Evidence ◽  
Benefit Analysis ◽  
Medication Effects ◽  
Current Evidence Base ◽  
Pregnancy And Lactation ◽  
Potential Risks ◽  
Risk Benefit Analysis

<p>Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary pharmacological treatment for moderate to severe depression during pregnancy.<span><em> </em></span>Data regarding the safety of their use during pregnancy remain controversial and conflicting. Decisions regarding the prescription of antidepressant treatment are often fraught with concern around potential harmful medication effects on the pregnancy, fetus and infant. Information on potential risks remains extremely varied and inconsistent across sources. This lack of clarity regarding drug safety brings significant uncertainty not only for treating physicians, but also for women seeking information about depression during pregnancy. This review aims to summarise and evaluate the current evidence base and to aid clinicians in performing a risk/benefit analysis for SSRI use during pregnancy and lactation.</p><div> </div>

Future of ToxicologyLow-Dose Toxicology and Risk−Benefit Analysis

2006 ◽  
Vol 19 (8) ◽  
pp. 977-981 ◽  
Author(s):  
Ivonne M. C. M. Rietjens ◽  
Gerrit M. Alink
Keyword(s):  
Benefit Analysis ◽  
Risk Benefit Analysis
Sign in / Sign up

Export Citation Format

Share Document